William Maier
Chief Scientific Officer
MAPI Group
Sweden
Biography
His promotion of a new pharmacoepidemiology, risk management, and research methodology—and his application of innovative technology to improve efficiency and accuracy of post-marketing surveillance studies—has proven invaluable to rare disease researchers. Dr. Maier has been involved in drug development and regulatory negotiations for products indicated for the following rare / orphan indications: Corneal cystine crystal deposits , Stem Cell Mobilisation in Healthy Donors , Severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS) following haematopoietic stem-cell transplantation (HSCT) therapy , Primary Immunodeficiency (PI) in adults. This included, but was not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott- Aldrich syndrome, and severe combined immunodeficiencies , Cystic Fibrosis Genetic variants of amyloid plaque development in Alzheimer’s Disease , Primary and secondary progressive Multiple Sclerosis , Crohn’s Disease andWilliam Maier, PhD, Mapi’s Chief Scientific Officer, has more than 20 years of drug development and commercialization experience, and he provides invaluable insight to sponsors. Ulcerative Colitis , Autosomal dominant polycystic kidney disease (ADPKD) , Levoleucovorin for Use In Combination Chemotherapy With 5-Fluorouracil In The Palliative Treatment Of Patients With Advanced Metastatic Colorectal Cancer: given orphan drug definition by FDA . He has also conducted research projects for the follow rare disease areas: Cushing’s syndrome ,Duchenne’s muscular dystrophy (DMD), Progressive Multifocal Leukoencephalopathy (PML),Niemann-Pick type C disease , Metastatic colorectal cancer (mCRC) , Malignant glioma Short bowel syndrome (SBS) , Dupuytren’s contracture , Achondroplasia Multiple myeloma.
Research Interest
His research interest in drug development and commercialization experience
